Aclaris Therapeutics
ACRS
148 hedge funds and large institutions have $579M invested in Aclaris Therapeutics in 2023 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 20 closing their positions.
100% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 20
33% more call options, than puts
Call options by funds: $26.5M | Put options by funds: $20M
16% more funds holding
Funds holding: 128 → 148 (+20)
8.64% more ownership
Funds ownership: 98.67% → 107.32% (+8.6%)
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
44% less capital invested
Capital invested by funds: $1.04B → $579M (-$456M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$43.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$25.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$24M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$21.7M |
| 5 |
SC
Samlyn Capital
New York
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$44.7M |
| 2 |
O
OrbiMed
New York
|
-$43.4M |
| 3 |
CC
Commodore Capital
New York
|
-$15.8M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$7.81M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$6.54M |
ACRS Hedge Fund Activity: Q1 2023 in Review
148 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2023, worth a combined $579M — down 44% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ACRS positions and 20 closed out — a net gain of 20 holders — while 43 added to existing stakes and 40 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $43.2M. The largest seller was VR Adviser, cutting an estimated $44.7M.
- 148 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2023, up from 128 in Q4 2022.
- Funds reported $579M of Aclaris Therapeutics stock for Q1 2023, down 44% quarter-over-quarter.
- 40 funds opened new Aclaris Therapeutics positions in Q1 2023 and 20 closed out, a net change of +20 holders.
- The largest Aclaris Therapeutics buyer in Q1 2023 was Bain Capital Life Sciences Investors, an estimated $43.2M added.
- The largest Aclaris Therapeutics seller in Q1 2023 was VR Adviser, an estimated $44.7M sold.
Based on aggregated 13F filings for Q1 2023.